- October 24, 2025 - Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at #ObesityWeek2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m
Geneva: World Health Organization
Ice crystal formation damages peptide structure irreversibly
Explore the benefits of B12 injections for enhancing your overall wellness and energy levels
The neurological consequences of untreated B12 deficiency can be serious and potentially permanent, including subacute combined degeneration of the spinal cord, which affects both sensory and motor pathways